Nick Paul Taylor

Eli Lilly has dropped (PDF) the lead candidate from its $2.4 billion takeover of Dice Thera

The filing follows Exactech’s failure to reach a settlement for product liability claims brought by around 2,600 patients in response to recalls of orthopedic devices.

Almirall has put patients' friends and family at the heart of its activities for the 2024 World Psoriasis Day,

Takeda has stopped (PDF) a phase 2 trial of dana

Compass Pathways' journey to phase 3 psychedelic depression data is taking longer than expected.

AbbVie's deal team is having a busy week. Days after inking a $1.4 billion buyout, the drugmaker has put up the same again in biobucks to secure options on multispecific T-cell engagers from EvolveImmune.

The three medtech firms unveiled new data this week during TCT 2024 in Washington, D.C. We look at what the results mean for the companies and their device markets.

The week after seeing its partner Roche cut and run, UCB has reported the failure of its anti-tau antibody bepranemab to improve cognition and function in people with early Alzheimer's disease.

The document clarifies that EtO falls within the scope of the Medical Device Regulation and the In Vitro Diagnostic Regulation.

NeuroOne will get $3 million upfront for an exclusive license to distribute its radiofrequency ablation system designed to treat neurological disorders such as epilepsy and Parkinson's disease.